The molecular pathogenesis of craniopharyngiomas

• Published in: Archives of Endocrinology and Metabolism Vol. 67; no. 2; pp. 266 - 275
• Main Authors: Campanini, Marina Lanciotti, Almeida, João Paulo, Martins, Clarissa Silva, de Castro, Margaret
• Format: Journal Article
• Language: English
• Published: Brazil Sociedade Brasileira de Endocrinologia e Metabologia 10.03.2023; Brazilian Society of Endocrinology and Metabolism
• Subjects: adamantinomatous; Adult; BRAF V600E; Child; Craniopharyngioma; Craniopharyngioma - genetics; Craniopharyngioma - metabolism; Craniopharyngioma - pathology; CTNNB1; Humans; molecular pathogenesis; Mutation - genetics; papillary; Pituitary Neoplasms - genetics; Review; Tumor Microenvironment; adamantinomatous; papillary; Craniopharyngioma; molecular pathogenesis
• ISSN: 2359-3997; 2359-4292
• DOI: 10.20945/2359-3997000000600

Research from the last 20 years has provided important insights into the molecular pathogenesis of craniopharyngiomas (CPs). Besides the well-known clinical and histological differences between the subtypes of CPs, adamantinomatous (ACP) and papillary (PCP) craniopharyngiomas, other molecular differences have been identified, further elucidating pathways related to the origin and development of such tumors. The present minireview assesses current knowledge on embryogenesis and the genetic, epigenetic, transcriptomic, and signaling pathways involved in the ACP and PCP subtypes, revealing the similarities and differences in their profiles. ACP and PCP subtypes can be identified by the presence of mutations in and genes, with prevalence around 60% and 90%, respectively. Therefore, β-catenin accumulates in the nucleus-cytoplasm of cell clusters in ACPs and, in PCPs, cell immunostaining with specific antibody against the V600E-mutated protein can be seen. Distinct patterns of DNA methylation further differentiate ACPs and PCPs. In addition, research on genetic and epigenetic changes and tumor microenvironment specificities have further clarified the development and progression of the disease. No relevant transcriptional differences in ACPs have emerged between children and adults. In conclusion, ACPs and PCPs present diverse genetic signatures and each subtype is associated with specific signaling pathways. A better understanding of the pathways related to the growth of such tumors is paramount for the development of novel targeted therapeutic agents.